Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No pharmacokinetic study for Testagen found on PubMed, PMC, or ClinicalTrials.gov.
No dosing study targeting testicular/endocrine endpoints found on allowed hosts. The only allowed-host papers are an in-vitro HeLa nuclear-penetration/DNA-binding assay and an unrelated electrochemistry paper testing the peptide as a corrosion inhibitor, neither establishes a biological dose.
Single Russian lineage. The only biological allowed-host study (Fedoreyeva et al., Biochemistry (Moscow) 2011) is an in-vitro nuclear-penetration/DNA-binding assay in HeLa cells, not a testes-specific efficacy or PK study. No in-vivo animal or human efficacy data, no independent Western replication, despite being marketed as a testicular bioregulator. Sequence Lys-Glu-Asp-Gly and MW 447.4 Da confirmed on PubChem (CID 123863700).
No human safety, toxicology, or adverse-event data for Testagen found on any allowed-host source. Absence of reported harm in the sparse literature is not evidence of safety, no controlled human safety trial has been published.
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in-vitro interaction of the peptides with deoxyribooligonucleotides and DNA · pubmed
- The Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces in Saline Environments · journal
- PubChem Compound Summary CID 123863700, H-Lys-Glu-Asp-Gly-OH (MW 447.4) · other